CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRSP 57.92 +0.35(0.61%)
Will CRSP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?
Other News for CRSP
Actinium wins FDA nod to conduct clinical trial for radiotherapy
JMP Securities healthcare analysts hold an analyst/industry conference call
TD Cowen Reaffirms Their Sell Rating on Crispr Therapeutics AG (CRSP)
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
3 Gene Editing Stocks Shaping the Future of Medicine